Survival Benefit of Palliative Gastrectomy in Gastric Cancer Patients with Peritoneal Metastasis
- 21 July 2012
- journal article
- research article
- Published by Wiley in World Journal of Surgery
- Vol. 36 (11), 2637-2643
- https://doi.org/10.1007/s00268-012-1721-y
Abstract
Background The survival benefit of palliative gastrectomy in patients with peritoneal metastasis as a single incurable factor remains unclear. Methods A total of 148 gastric cancer patients with peritoneal metastasis underwent gastrectomy or chemotherapy at the Shizuoka Cancer Center between September 2002 and December 2008 and were included in this study. The effects of gastrectomy and chemotherapy on their long-term outcome were investigated. Multivariate analysis was also performed to identify independent prognostic factors. Results Gastrectomy was performed in 82 patients and subsequent chemotherapy was administered to 55. Chemotherapy was selected as an initial treatment for 66 patients. Median survival time (MST) was identical between patients with and without gastrectomy (13.1 vs. 12.0 months; P = 0.410). Conversely, MST was significantly longer in patients who received chemotherapy (13.7 months) than those who did not (7.1 months; P = 0.048). According to the results of multivariate analysis, chemotherapy (hazards ratio [HR] = 0.476; 95 % CI = 0.288–0.787) was selected as an independent prognostic factor, while gastrectomy was not. Conclusions The results of the present study did not show a survival benefit of palliative gastrectomy in selected patients with peritoneal metastasis. Instead, chemotherapy has to be considered as an initial treatment for these patients.This publication has 33 references indexed in Scilit:
- Counting the cost of cancer surgery for advanced and metastatic diseaseBritish Journal of Surgery, 2012
- Gastric cancer treatment in Japan: 2008 annual report of the JGCA nationwide registryGastric Cancer, 2011
- Survival benefit of gastrectomy ± metastasectomy in patients with metastatic gastric cancer receiving chemotherapyGastric Cancer, 2011
- Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trialThe Lancet, 2010
- Can Superextended Lymph Node Dissection be Justified for Gastric Cancer with Pathologically Positive Para-aortic Lymph Nodes?Annals of Surgical Oncology, 2010
- S-1 plus cisplatin versus S-1 alone for first-line treatment of advanced gastric cancer (SPIRITS trial): a phase III trialThe Lancet Oncology, 2008
- Adjuvant Chemotherapy for Gastric Cancer with S-1, an Oral FluoropyrimidineThe New England Journal of Medicine, 2007
- Liver Resection for Metastatic Gastric Cancer: Experience with 42 Patients Including Eight Long-term SurvivorsJapanese Journal of Clinical Oncology, 2007
- Gastric cancer treated in 1991 in Japan: data analysis of nationwide registryGastric Cancer, 2006
- Hepatic resection for the treatment of liver metastases in gastric carcinoma: review of the literatureHPB, 2006